Press Releases Year All202020192018 03/31/20 Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and Hyperinflammation 03/30/20 Kiniksa Highlights Phase 2 Study Data Showing the Corticosteroid-Sparing Effect of Rilonacept in Patients with Recurrent Pericarditis at the American College of Cardiology's 69th Annual Scientific Session 02/26/20 Kiniksa Reports Fourth Quarter and Full-Year 2019 Financial Results and Highlights Recent Pipeline Activity 01/13/20 Kiniksa Announces Pipeline Progress and Reiterates 2020 Clinical Data Readouts 12/11/19 Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma 12/10/19 Kiniksa Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference 11/20/19 Kiniksa Pharmaceuticals to Present at the 2nd Annual Evercore ISI HealthCONx Conference 11/20/19 Kiniksa Announces Breakthrough Therapy Designation for Rilonacept for the Treatment of Recurrent Pericarditis 11/16/19 Kiniksa Presents Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019 11/12/19 Kiniksa Presents Preclinical Data on the Role of GM-CSF in GCA at the 2019 ACR/ARP Annual Meeting 10/28/19 Kiniksa Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity 09/19/19 Kiniksa Presents Preclinical Data Supporting KPL-716 Clinical Development at the 49th Annual Meeting of the European Society of Dermatological Research 08/19/19 Kiniksa to Present Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019 08/12/19 Kiniksa Reports Second Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity 08/12/19 Kiniksa Announces Interim Data from KPL-716 Repeated-Single-Dose Phase 1b Clinical Trial 08/06/19 Kiniksa Pharmaceuticals to Present at the 2019 Wedbush PacGrow Healthcare Conference 08/05/19 Kiniksa Pharmaceuticals Announces Collaboration with the Myocarditis Foundation for the Pericarditis Community 06/12/19 Kiniksa Presents Preclinical Data on the GM-CSF Signaling Pathway in Temporal Arteries of GCA Patients at the Annual European Congress of Rheumatology 05/30/19 Kiniksa to Present Preclinical Data on the GM-CSF Signaling Pathway in Temporal Arteries of GCA Patients at EULAR 2019 05/29/19 Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences 05/16/19 Kiniksa to Present Data on the Burden of Disease in Patients with Recurrent Pericarditis at the International Society for Pharmacoeconomics and Outcomes Research 05/13/19 Kiniksa Presents Clinical and Preclinical Data for KPL-716 at the 77th Annual Meeting of the Society for Investigative Dermatology 05/02/19 Kiniksa Reports First Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity 04/17/19 Kiniksa to Present Clinical and Preclinical Data for KPL-716 at the 77th Annual Meeting of the Society for Investigative Dermatology 04/08/19 Kiniksa to Present KPL-404 Preclinical Data at the Keystone Symposia on Antibodies as Drugs 03/18/19 Kiniksa Presents Rilonacept Interim Phase 2 Clinical Data Poster at the American College of Cardiology’s 68th Annual Scientific Session 03/07/19 Kiniksa Reports Fourth Quarter and Full-Year 2018 Financial Results and Highlights Recent Corporate and Pipeline Activity 02/28/19 Kiniksa Pharmaceuticals to Present at the Cowen and Company 39th Annual Healthcare Conference 02/26/19 Kiniksa Pharmaceuticals to Present at the Barclays Global Healthcare Conference 01/31/19 Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering 01/28/19 Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering and Concurrent Private Placement 01/03/19 Kiniksa Announces Active U.S. Investigational New Drug Application for Mavrilimumab 12/17/18 Kiniksa Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference 12/11/18 Kiniksa Announces Rilonacept Interim Phase 2 Clinical Data and Initiates Pivotal Phase 3 Clinical Trial 12/06/18 Kiniksa Provides Update on U.S. FDA Review of Investigational New Drug Application for Mavrilimumab in Giant Cell Arteritis 11/01/18 Kiniksa Reports Third Quarter 2018 Financial Results and Pipeline Progress 09/15/18 Kiniksa Presents KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology 08/29/18 Kiniksa to Present Late-Breaking KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology 08/28/18 Kiniksa Pharmaceuticals to Present at the 2018 Wells Fargo Healthcare Conference 08/06/18 Kiniksa Reports Second Quarter 2018 Financial Results and Pipeline Progress 08/02/18 Kiniksa Pharmaceuticals to Present at the 2018 Wedbush PacGrow Healthcare Conference 06/25/18 Kiniksa Pharmaceuticals, Ltd. Announces Exercise of the Underwriters’ Option to Purchase Additional Shares 06/14/18 Kiniksa Pharmaceuticals to Present at the JMP Securities 2018 Life Sciences Conference 05/29/18 Kiniksa Pharmaceuticals, Ltd. Announces Closing of Initial Public Offering 05/23/18 Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Initial Public Offering 12/21/17 Kiniksa Pharmaceuticals to Present at 36th Annual J.P. Morgan Healthcare Conference 12/20/16 Sanj K. Patel to Introduce Kiniksa Pharmaceuticals at 35th Annual J.P. Morgan Healthcare Conference
